MaaT Pharma SA (MAAT.PA)
EUR 8.1
(1.0%)
EUR 8.1
(1.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -19.94 Million EUR | -81.54% |
| 2022 | -13.55 Million EUR | -52.43% |
| 2021 | -8.89 Million EUR | -69.33% |
| 2020 | -5.25 Million EUR | -5.78% |
| 2019 | -4.96 Million EUR | -12.74% |
| 2018 | -4.4 Million EUR | 6.46% |
| 2017 | -4.7 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.37 Million EUR | -11.81% |
| 2024 Q2 | -6.37 Million EUR | 0.0% |
| 2023 Q1 | -4.26 Million EUR | 49.89% |
| 2023 Q2 | -11.27 Million EUR | -164.18% |
| 2023 FY | -24.61 Million EUR | -81.54% |
| 2023 Q3 | -5.7 Million EUR | 49.41% |
| 2023 Q4 | -5.7 Million EUR | -0.01% |
| 2022 FY | -13.55 Million EUR | -52.43% |
| 2022 Q4 | -8.51 Million EUR | -175.27% |
| 2022 Q3 | -3.09 Million EUR | 66.23% |
| 2022 Q2 | -9.16 Million EUR | -148.67% |
| 2022 Q1 | -3.68 Million EUR | 39.73% |
| 2021 Q4 | -6.11 Million EUR | -148.91% |
| 2021 FY | -8.89 Million EUR | -69.33% |
| 2021 Q3 | -2.45 Million EUR | 52.51% |
| 2021 Q2 | -5.17 Million EUR | -159.72% |
| 2021 Q1 | -1.99 Million EUR | 51.62% |
| 2020 FY | -5.25 Million EUR | -5.78% |
| 2020 Q3 | -1.55 Million EUR | 52.41% |
| 2020 Q2 | -3.27 Million EUR | -206.32% |
| 2020 Q1 | -1.06 Million EUR | 0.0% |
| 2020 Q4 | -4.11 Million EUR | -164.21% |
| 2019 FY | -4.96 Million EUR | -12.74% |
| 2018 FY | -4.4 Million EUR | 6.46% |
| 2017 FY | -4.7 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -484.496% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 84.343% |
| Adocia SA | -17.62 Million EUR | -13.171% |
| Aelis Farma SA | -6.46 Million EUR | -208.667% |
| Biophytis S.A. | -14.33 Million EUR | -39.14% |
| Advicenne S.A. | -6.45 Million EUR | -208.859% |
| genOway Société anonyme | 2.06 Million EUR | 1065.624% |
| IntegraGen SA | -183.77 Thousand EUR | -10752.152% |
| Medesis Pharma S.A. | -4.22 Million EUR | -371.539% |
| Neovacs S.A. | -6.9 Million EUR | -188.713% |
| NFL Biosciences SA | -4.43 Million EUR | -350.138% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -2462.587% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -535.683% |
| Sensorion SA | -22.31 Million EUR | 10.612% |
| Theranexus Société Anonyme | -7.64 Million EUR | -160.908% |
| TME Pharma N.V. | -5.62 Million EUR | -254.605% |
| Valbiotis SA | -7.16 Million EUR | -178.534% |
| TheraVet SA | -2.17 Million EUR | -816.874% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 1.701% |
| argenx SE | -417.15 Million EUR | 95.219% |
| BioSenic S.A. | -7.04 Million EUR | -183.281% |
| Celyad Oncology SA | -8.45 Million EUR | -135.816% |
| DBV Technologies S.A. | -85.24 Million EUR | 76.605% |
| Galapagos NV | -88.26 Million EUR | 77.405% |
| Genfit S.A. | -26.58 Million EUR | 24.97% |
| GeNeuro SA | -14.35 Million EUR | -38.905% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -24.698% |
| Innate Pharma S.A. | -12.66 Million EUR | -57.416% |
| Inventiva S.A. | -102.7 Million EUR | 80.583% |
| MedinCell S.A. | -20.97 Million EUR | 4.929% |
| Nanobiotix S.A. | -26.77 Million EUR | 25.527% |
| Onward Medical N.V. | -35.46 Million EUR | 43.764% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -338.385% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 13.238% |
| Oxurion NV | -12.11 Million EUR | -64.682% |
| Pharming Group N.V. | -4.87 Million EUR | -308.706% |
| Poxel S.A. | -28.76 Million EUR | 30.667% |
| GenSight Biologics S.A. | -29.69 Million EUR | 32.843% |
| Transgene SA | -30.01 Million EUR | 33.55% |
| Financière de Tubize SA | -2.14 Million EUR | -830.189% |
| UCB SA | 604 Million EUR | 103.302% |
| Valneva SE | -82.08 Million EUR | 75.705% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 30.842% |